Skip to main content
Equibles
ACRS logo

ACRS · Aclaris Therapeutics, Inc. · Metrics

Track ACRS — free

Use ACRS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACRS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.77 +0.29 (+8.33%) At close · Oct 20
Russell 2000 member Rebalance outlook locked
Market Cap
$543.90M
Shares
147.20M
Volume · Oct 20 3.5M Avg daily vol (3M) 2.72M

ACRS metrics

85 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.77
Market cap
$543.90M

Price action

20 metrics
Price change (1W)
-3.3%
Price change (30D)
-37.5%
Price change (3M)
-37.5%
Price change (6M)
-18.1%
Price change (YTD)
+15.6%
Price change (1Y)
+83.2%
Trailing year
Price change (5Y)
-78.4%
52-week high
$6.54
52-week low
$2.01
Change from 52-week high
-46.7%
Change from 52-week low
+73.1%
Annualized volatility
100.6%
Annualized volatility (3M)
75.8%
Beta
0.5
RSI (14D)
33.0
Price vs SMA 50
-34.0%
Price vs SMA 200
-22.3%
Avg volume (3M)
2.68M
Relative volume
0.7
Average dollar volume
$13.58M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
147.20M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
57.8×
reciprocal yield 1.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
60.1×
reciprocal yield 1.7%
P / book
4.0
reciprocal yield 25.2%
FCF yield
-12.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-15.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
27.7×
reciprocal yield 3.6%
EV / revenue historical average (5Y)
54.4×
reciprocal yield 1.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-04-28

Profitability

9 metrics
Gross margin
—
Operating margin
-1,050.2%
Trailing 12 months
Net margin
-921.5%
Gross profit (TTM)
$3.24M
Operating profit (TTM)
−$86.31M
Net income (TTM)
−$75.74M
Trailing 12 months
Diluted EPS (TTM)
$-0.58
FCF margin
-756.5%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.06
Gross profit per diluted share (TTM)
$0.11
Operating profit per diluted share (TTM)
$-0.67
EBITDA per diluted share (TTM)
$-0.66
Net income per diluted share (TTM)
$-0.59
Operating cash flow per diluted share (TTM)
$-0.48
Free cash flow per diluted share (TTM)
$-0.48
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.49
Stock compensation per diluted share (TTM)
$0.09
Book value per share
$0.86

Growth

11 metrics
Revenue growth YoY
-8.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$8.22M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+16.4%
Year over year · more shares
Revenue CAGR (3Y)
-35.9%
Revenue CAGR (5Y)
+3.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-60.8%
Return on assets
-42.1%
Debt / equity
0.0
Current ratio
3.5
EBITDA (TTM)
−$85.89M
Free cash flow (TTM)
−$62.18M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$19.17M
Latest balance sheet
Cash & equivalents
$19.17M
Total assets
$179.69M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$62.06M
Capital expenditures (TTM)
$118,000
R&D (TTM)
$63.34M
SG&A (TTM)
—
Stock compensation (TTM)
$11.66M
R&D / revenue
770.6%
Stock compensation / revenue
141.8%

Ownership (13F)

9 metrics
13F filers
149
13F filer change QoQ
+12
Institutional ownership
81.5%
Conviction holders (share of 13F filers)
4.1%
Crowding (high-turnover and private-fund holders)
49.2%
Private-fund adviser ownership
48.1%
Active holders' share change QoQ
+7.2%
Holder tenure
8.5
Price vs estimated holder cost
+79.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.1%

Short interest

3 metrics
Short interest
12.4%
Latest settlement · 6.5 days to cover
Days to cover
6.5d
Short-squeeze score
76 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1557746 CUSIP 00461U105 13F (30d) 12 filings 12 filers Visit website Investor relations